ImmuneRegen News

$15 Million in Government funding to Research Immuneregen Bioscience’s Homspera®

August 25, 2010

ImmuneRegen BioSciences® Completes Successful Reduction of Debts

August 4, 2010

Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre, the Netherlands

April 28, 2010

ImmuneRegen BioSciences® Initiates Strategic Collaboration With MPI Research to Accelerate Clinical Development of Lead Indications

April 21, 2010

ImmuneRegen BioSciences Submits Homspera® for FDA Orphan Drug Product Designation for the Treatment of Idiopathic Pulmonary Fibrosis

March 4, 2010

Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences' Cancer Therapy Candidate

February 10, 2010

National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate

January 27, 2010

ImmuneRegen BioSciences® Reports Additional Positive Results From Study of Homspera® in Treating Highly Pathogenic Influenza

January 5, 2010

ImmuneRegen BioSciences® Summarizes Previous 9 Months of Advances as Homspera® Development Continues

December 24, 2009

ImmuneRegen BioSciences'® Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine

December 21, 2009

ImmuneRegen BioSciences'® Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant

December 14, 2009

ImmuneRegen BioSciences® Reports Positive Results of Homspera® in Treating Highly Pathogenic Influenza

Novemeber 10, 2009

ImmuneRegen BioSciences® to Further Homspera® Research in Study Funded by U.S. Government

October 22, 2009

ImmuneRegen BioSciences® Initiates Homspera® Studies Against Global Influenza Threat

October 12, 2009

ImmuneRegen BioSciences® Announces Strategic Partnership With Azopharma Product Development Group, Inc.

September 23, 2009

ImmuneRegen BioSciences® Announces Partnership with Bachem, Inc., for Manufacturing of Homspera®

September 22, 2009

ImmuneRegen BioSciences® Partners with University of Rochester in BARDA Funding Bid

September 9, 2009

ImmuneRegen BioSciences® Announces Collaboration with Archimedes Development Limited

August 26, 2009

ImmuneRegen BioSciences® Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus after Oral Administration

July 29, 2009

ImmuneRegen BioSciences® Announces IND Submission for Homspera® for the Treatment of Idiopathic Pulmonary Fibrosis

May 28, 2009

ImmuneRegen BioSciences® Enters into a Sponsored Research Agreement with the University of Pittsburgh

May 14, 2009

ImmuneRegen® Licenses Intellectual Property from University of Pittsburgh to Further Develop Proprietary Compound

April 30, 2009

ImmuneRegen BioSciences® Adds Renowned Scientists to Advisory Board

April 14, 2009

ImmuneRegen® BioSciences Partners with University of Rochester Scientist to Explore Homspera® Activity Against Pulmonary Fibrosis

April 7, 2009

ImmuneRegen® BioSciences to Present Homspera® Findings at BIO 2009

March 26, 2009

WaferGen Biosystems, ImmuneRegen® BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research

March 24, 2009

ImmuneRegen® Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board

December 1, 2008

ImmuneRegen® BioSciences to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference

November 6, 2008

ImmuneRegen® Scientist to Present Viprovex® Pre-Clinical Study Findings at 2008 BARDA Industry Day

September 24, 2008

UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegen's Viprovex® With Cancer Vaccine

September 23, 2008

ASU's Biodesign Institute and ImmuneRegen® Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses

August 18, 2008

ImmuneRegen® BioSciences Confirms Homspera® Advances Wound Healing in Topical Application

August 13, 2008

IR BioSciences Holdings, Inc. Closes New $5 Million Funding Round

August 11, 2008

ImmuneRegen® BioSciences Advances Toward IND Filing

July 17, 2008

ImmuneRegen® BioSciences Confirms Adult Stem Cell Activity of Homspera® in Human Bone Marrow

June 9, 2008

ImmuneRegen® Appoints Renowned Hematologist Ivan N. Rich, Ph.D. to Advisory Board

May 6, 2008

ImmuneRegen® BioSciences to Provide Adjuvant to DynPort Vaccine Company for Development of an Inactivated Vaccine against Venezuelan Equine Encephalitis Virus

April 30, 2008

ImmuneRegen® and BioCure Collaborate on Novel Wound-Healing Product

April 24, 2008

ImmuneRegen® Releases Results from UMDNJ Study Confirming Homspera's Adult Stem Cell Activity

April 16, 2008

ImmuneRegen® BioSciences Signs Material Transfer Agreement with University of Medicine and Dentistry of New Jersey

April 1, 2008

ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity

March 27, 2008

ImmuneRegen® BioSciences and DelSite Biotechnologies Collaborate On New Flu Treatment

March 24, 2008

ImmuneRegen® BioSciences Signs Lovelace Respiratory Research Institute as Development and Regulatory Partner

February 19, 2008

ImmuneRegen® BioSciences Announces Material Transfer Agreement with HemoGenix®

January 28, 2008

ImmuneRegen® BioSciences Signs Material Transfer Agreement with Celgene Cellular Therapeutics

January 23, 2008

IR BioSciences Announces $3 Million Financing Agreement

January 9, 2008